SYS-CON MEDIA Authors: Yeshim Deniz, Doug Masi, Mat Mathews, PR.com Newswire, David Smith

News Feed Item

Global Markets and Technologies for Advanced Drug Delivery Systems

NEW YORK, Jan. 9, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:



Global Markets and Technologies for Advanced Drug Delivery Systems


http://www.reportlinker.com/p01940407/Global-Markets-and-Technologies-fo...



STUDY OBJECTIVES

A drug delivery system is one of the very important aspects in today's growth in the pharmaceutical industry. BCC Research's goal in steering this study is to provide an overview of the current and future characteristics of the market for these drug delivery systems. The key objective is to present a comprehensive analysis and future direction of these drug delivery systems as an important tool in improving the efficacy and safety of the release of drugs in the body.


This report explores the present and future strategies within the drug delivery market, which includes sustained release drug delivery, prodrug, implants and intrauterine devices (IUDs), targeted drug delivery, polymeric drug delivery, transdermal drug delivery, and transmucosal drug delivery systems. The improvisation of the market and the setbacks and the needs of the market are discussed in this report. The classifications, comparisons and usage of these types of drug delivery systems are also portrayed in this report.


A detailed analysis of drug delivery industry structure has been conducted. Revenues are broken down by region. Sales figures are estimated for the five-year period from 2013 through 2018.


Applications for drug delivery systems are also discussed in the report, with emphasis on the usage of these systems in various therapeutic categories and various disease sectors. The report also covers significant patents and their allotments in each category.



REASONS FOR DOING THIS STUDY

Extensive research in the field of various drug delivery systems has revealed their specific functionality in improving the transportation of a pharmaceutical compound in the body as desired to safely achieve its anticipated therapeutic effect. Modern industries have now begun to explore the advantages of these drug delivery systems in their productions and processes. This has led to the steady market for those drug delivery systems.


R&D spending, along with increasing competition, patent expiries and new technologies, are directing this in a new direction. The new advancements and new product launches have influenced the market to grow in the foreseeable future. This study looks at almost all the systems affected by these factors.


Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strengths and weaknesses of each type/technology in light of the new technologies, growing competition and changing customer needs.



INTENDED AUDIENCE

This study contributes to the areas of market growth in various drug delivery systems manufacturers and users. Pharmaceutical biotechnical companies and research institutes will find this study to be of interest.



SCOPE OF THE STUDY

The scope of this study encompasses drug delivery systems in pharmaceutical and biotechnology markets. BCC Research analyzes each market by its type, region and its applications, regulatory environment, technology, market projections and market share. Technological issues include the latest trends and developments. The emerging markets for drug delivery systems include countries such as India, China, Japan, Korea, Taiwan, Canada, Africa, Australia, New Zealand and so forth.



METHODOLOGY

Both primary and secondary research methodologies were used in preparing this study. BCC Research conducted a comprehensive literature search, which included technical newsletters and journals, and many other sources. Data were collected through interviews and correspondence with manufacturers of drug delivery systems and technical experts. Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, new developments and market trends.



INFORMATION SOURCES

Many companies were surveyed to obtain data for this study. Included were manufacturers and end users of drug delivery systems in therapeutic categories and various disease sectors industries. Data were gathered from various industry sources. BCC Research spoke with officials within the industry, consulted newsletters, company literature, product literature, and a host of technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade and government sources.



ABOUT THE AUTHOR

A team of professionals in the biotechnology industry carried out this study. The project manager is Shalini S. Dewan, who holds a master's degree in pharmaceutical chemistry and has over 14 years' of industry experience. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Shalini was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S. Some of her other reports with BCC Research are: Reagents for Chromatography; Spectroscopy: An Enduring Market; Advanced Drug Delivery Systems: Technologies and Global Markets; Orthopedic Drugs, Implants and Devices; Medical Imaging Reagents and Analysis Equipment; Pharmaceutical Regulatory Industry; The Dynamic Media, Sera and Reagent Market in Biotechnology; Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets; Chiral Technology: Global Markets; Autacoids and Related Drugs: Technologies and Global Markets; Contraceptives: Technologies and Global Markets; Liver Disease Treatments: The Global Market; Hormone Replacement Therapies and Other Hormone Therapies: Global Markets; Cardiovascular Medicine: Diagnostics, Drugs and Devices; and Cancer Therapies: Technologies and Global Markets.



REPORT HIGHLIGHTS

The global revenue for advanced drug delivery systems is estimated to be $181.9 billion in 2013. In 2018, revenues are estimated to reach $212.8 billion, demonstrating a compound annual growth rate (CAGR) of 3.2%.


This report provides:


• An overview of the global market for drug delivery systems, including the market as seen by the end users of the different applications.


• Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.


• Discussion of the current state, setbacks, innovations, and the future needs of the market.


• Examination of the different categories of drug delivery, broken down by market shares of the leading manufacturers and/or suppliers, as well as acquisitions, mergers, and alliances by companies and global organizations.


• Analyses of the regulatory environment, and the technology involved, including the latest trends and developments.




TABLE OF CONTENTS

CHAPTER 1 INTRODUCTION 2

STUDY OBJECTIVES 2


REASONS FOR DOING THIS STUDY 2


INTENDED AUDIENCE 3


SCOPE OF THE STUDY 3


METHODOLOGY 3


INFORMATION SOURCES 3


ABOUT THE AUTHOR 3


RELATED BCC RESEARCH REPORTS 4


BCC RESEARCH ONLINE SERVICES 4


DISCLAIMER 4



CHAPTER 2 SUMMARY 6

SUMMARY TABLE GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS,BY


REGION, THROUGH 2018 ($ MILLIONS) 7


SUMMARY FIGURE GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS,BY


REGION, 2011-2018 ($ MILLIONS) 7



CHAPTER 3 OVERVIEW 9

NEED FOR THE DOSAGE FORMS 9


TABLE 1 HISTORIC EVENTS IN DRUG DELIVERY 10


CLASSIFICATION OF DRUG DELIVERY ACCORDING TO TECHNOLOGY 11


SUSTAINED RELEASE DRUG DELIVERY 11


Oral Sustained Release Drug Delivery 11


Intramuscular (IM) Injections or Microsyringes 12


TABLE 2 ADVANTAGES AND DISADVANTAGES OF SUSTAINED RELEASE DRUG


DELIVERY 12


PRODRUGS 13


Subtypes of Prodrugs 14


TABLE 3 CLASSIFICATION OF PRODRUGS 14


Need for Prodrugs 15


TABLE 4 ADVANTAGES AND DISADVANTAGES OF PRODRUGS 15


IMPLANTS AND INTRAUTERINE DEVICES (IUDS) 16


Copper-based Devices 16


Hormonal-based Devices 16


Mechanism 17


TABLE 5 ADVANTAGES AND DISADVANTAGES OF IMPLANTS AND IUDS 17


TARGETED DRUG DELIVERY 18


Delivery Vehicles 18


Liposomes 18


TABLE 6 ADVANTAGES AND DISADVANTAGES OF LIPOSOMES 19


Micelles and Dendrimers 19


Mechanisms of Drug Delivery 19


Advantages of Dendrimers 20


Biodegradable Particles 20


Artificial DNA Nanostructures 20


Monoclonal Antibodies 21


Applications 21


TABLE 7 ADVANTAGES AND DISADVANTAGES OF MONOCLONAL ANTIBODIES 22


POLYMERIC DRUG DELIVERY 22


Applications of Polymers in Drug Delivery 22


TABLE 8 ADVANTAGES AND DISADVANTAGES OF POLYMERS 23


Pegylation 23


TABLE 9 ADVANTAGES AND DISADVANTAGES OF PEGYLATION 24


Future Perspectives 24


CLASSIFICATION OF DRUG DELIVERY BY ROUTE OF ADMINISTRATION 24


ORAL DRUG DELIVERY 24


TABLE 10 ADVANTAGES AND DISADVANTAGES OF ORAL DRUG DELIVERY 25


INJECTABLE OR PARENTERAL DRUG DELIVERY 25


TABLE 11 ADVANTAGES AND DISADVANTAGES OF PARENTRAL DRUG DELIVERY 25


PULMONARY DRUG DELIVERY 26


TABLE 12 ADVANTAGES AND DISADVANTAGES OF PULMONARY DRUG DELIVERY 26


NASAL DRUG DELIVERY 27


TABLE 13 ADVANTAGES AND DISADVANTAGES OF NASAL DRUG DELIVERY 27


ORAL MUCOSAL DRUG DELIVERY 27


TABLE 14 ADVANTAGES AND DISADVANTAGES OF ORAL MUCOSAL DRUG


DELIVERY 28


RECTAL DRUG DELIVERY 28


TABLE 15 ADVANTAGES AND DISADVANTAGES OF RECTAL DRUG DELIVERY 28


OCULAR DRUG DELIVERY 29


TABLE 16 ADVANTAGES AND DISADVANTAGES OF OCULAR DRUG DELIVERY 29


TRANSDERMAL DRUG DELIVERY 29


TABLE 17 ADVANTAGES AND DISADVANTAGES OF TRANSDERMAL DRUG DELIVERY 29



CHAPTER 4 REGULATORY ASPECTS 32

NEW PRODUCTS APPROVED IN 2009-2013 32


TABLE 18 FDA-APPROVED NEW PRODUCTS, 2009-JULY 2013 32


FDA RECALLS AND SAFETY ALERTS 35


TABLE 19 PRODUCT RECALLS: DRUG DELIVERY, 2009-JUNE 2013 35


TABLE 20 SAFETY ALERTS, 2009 TO JUNE 2013 37



CHAPTER 5 NEW DEVELOPMENTS 40

NEW PARTNERSHIPS, MERGERS AND ACQUISITION 40


TABLE 21 NEW PARTNERSHIPS, MERGERS AND ACQUISITIONS, 2009-JUNE 2013 41


NEW PRODUCTS 42


TABLE 22 NEW INNOVATIONS IN DRUG DELIVERY, 2009-JUNE 2013 43


PIPELINE PRODUCTS 44


TABLE 23 PIPELINE PRODUCTS FOR DRUG DELIVERY MARKET 44



CHAPTER 6 GLOBAL MARKETS 46

MARKET BY TYPE 46


MARKET OVERVIEW 46


MARKET REVENUE 49


TABLE 24 GLOBAL REVENUE OF DRUG DELIVERY SYSTEMS BY TYPE, THROUGH


2018 ($ MILLIONS) 49


FIGURE 1 GLOBAL REVENUE OF DRUG DELIVERY SYSTEMS BY TYPE, 2011-2018 ($


MILLIONS) 49


MARKET SHARE 50


TABLE 25 MARKET SHARE OF DRUG DELIVERY SYSTEMS BY TYPE, 2012 (%) 50


FIGURE 2 MARKET SHARE OF DRUG DELIVERY SYSTEMS BY TYPE, 2012 (%) 51


MARKET BY REGION 51


SUSTAINED RELEASE DRUG DELIVERY SYSTEM 51


Market Overview 52


Market Revenue 53


TABLE 26 GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION,


THROUGH 2018 ($ MILLIONS) 53


FIGURE 3 GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION,


2011-2018 ($ MILLIONS) 53


Market Share 54


TABLE 27 MARKET SHARE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION,


FOR 2012 (%) 54


FIGURE 4 MARKET SHARE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION,


FOR 2012 (%) 54


PRODRUGS 54


Market Overview 55


Market Revenue 55


TABLE 28 GLOBAL REVENUE OF PRODRUGS DRUG DELIVERY BY REGION,


THROUGH 2018 ($ MILLIONS) 55


FIGURE 5 GLOBAL REVENUE OF PRODRUGS DRUG DELIVERY BY REGION,


2011-2018 ($ MILLIONS) 55


Market Share 56


TABLE 29 MARKET SHARE OF PRODRUGS DRUG DELIVERY, BY REGION, 2012 (%) 56


FIGURE 6 MARKET SHARE OF PRODRUGS DRUG DELIVERY BY REGION, 2012 (%) 56


IMPLANTS AND IUDS 57


Market Overview 57


Market Revenue 57


TABLE 30 GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, THROUGH 2018


($ MILLIONS) 58


FIGURE 7 GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, 2011-2018 ($


MILLIONS) 58


Market Share 58


TABLE 31 MARKET SHARE OF IMPLANTS AND IUDS BY REGION, 2012 (%) 59


FIGURE 8 MARKET SHARE OF IMPLANTS AND IUDS BY REGION, 2012 (%) 59


TRANSMUCOSAL DELIVERY SYSTEMS 59


Market Overview 60


Market Revenue 62


TABLE 32 GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION,


THROUGH 2018 ($ MILLIONS) 62


FIGURE 9 GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION,


2011-2018 ($ MILLIONS) 62


Market Share 63


TABLE 33 MARKET SHARE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2012


(%) 63


FIGURE 10 MARKET SHARE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2012


(%) 63


TARGETED DRUG DELIVERY 63


Market Overview 64


Market Revenue 65


TABLE 34 GLOBAL REVENUE OF TARGETED DRUG DELIVERY BY REGION, THROUGH


2018 ($ MILLIONS) 65


FIGURE 11 GLOBAL REVENUE OF TARGETED DRUG DELIVERY BY REGION,


2011-2018 ($ MILLIONS) 65


Market Share 66


TABLE 35 MARKET SHARE OF TARGETED DRUG DELIVERY BY REGION, 2012 (%) 66


FIGURE 12 MARKET SHARE OF TARGETED DRUG DELIVERY BY REGION, 2012 (%) 66


TRANSDERMAL DRUG DELIVERY SYSTEM 66


Market Overview 67


Market Revenue 67


TABLE 36 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION,


THROUGH 2018 ($ MILLIONS) 67


FIGURE 13 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION,


2011-2018 ($ MILLIONS) 68


Market Share 68


TABLE 37 MARKET SHARE OF TRANSDERMAL DRUG DELIVERY SYSTEM BY REGION,


2012 ($ MILLIONS) 68


FIGURE 14 MARKET SHARE OF TRANSDERMAL DRUG DELIVERY SYSTEMS BY


REGION, 2012 (%) 68


POLYMERIC DRUG DELIVERY 69


Market Overview 69


Market Revenue 70


TABLE 38 GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION,


THROUGH 2018 ($ MILLIONS) 70


FIGURE 15 GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION,


2011-2018 ($ MILLIONS) 70


Market Share 71


TABLE 39 MARKET SHARE OF POLYMERIC DRUG DELIVERY BY REGION, 2012 (%) 71


FIGURE 16 MARKET SHARE OF POLYMERIC DRUG DELIVERY BY REGION, 2012 (%) 71


MARKET BY END USERS 71


MARKET OVERVIEW 72


MARKET REVENUE 76


TABLE 40 GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY


APPLICATIONS, THROUGH 2018 ($ MILLIONS) 77


FIGURE 17 GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY


APPLICATIONS, 2011-2018 ($ MILLIONS) 77


MARKET SHARE 78


TABLE 41 MARKET SHARE OF DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS,


2012 (%) 79


FIGURE 18 MARKET SHARE OF DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS,


2012 (%) 79



CHAPTER 7 MARKET ANALYSIS FOR ADVANCED DRUG DELIVERY SYSTEMS BY TECHNOLOGY 81

TABLE 42 GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS BY


TECHNOLOGY, THROUGH 2018 ($ MILLIONS) 81


FIGURE 19 GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS BY


TECHNOLOGY, 2011-2018 ($ MILLIONS) 81


MARKET BY TYPE 82


SUSTAINED RELEASE 83


Market Overview 83


Market Revenue 84


TABLE 43 GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY SYSTEMS BY


TYPE, THROUGH 2018 ($ MILLIONS) 85


FIGURE 20 GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY SYSTEMS


BY TYPE, 2011-2018 ($ MILLIONS) 85


PRODRUGS 85


Market Overview 86


Market Revenue 86


TABLE 44 GLOBAL REVENUE OF PRODRUGS, THROUGH 2018 ($ MILLIONS) 86


TABLE 21 NEW PARTNERSHIPS, MERGERS AND ACQUISITIONS, 2009-JUNE 2013 87


IMPLANTS AND IUDS 88


Market Overview 89


Market Revenue 89


TABLE 45 GLOBAL REVENUE OF IMPLANTS AND IUDS*, THROUGH 2018 ($


MILLIONS) 89


FIGURE 22 GLOBAL REVENUE OF IMPLANTS AND IUDS*, 2011–2018 ($ MILLIONS) 89


TARGETED DRUG DELIVERY 90


Market Overview 90


Liposomes 90


Nanoparticles 91


Monoclonal Antibodies 91


Market Revenue 92


TABLE 46 GLOBAL REVENUE OF TARGETED DRUG DELIVERY SYSTEMS, THROUGH


2018 ($ MILLIONS) 92


FIGURE 23 GLOBAL REVENUE OF TARGETED DRUG DELIVERY SYSTEMS, 2011-2018


($ MILLIONS) 93


POLYMERIC DRUG DELIVERY 93


Market Overview 93


Market Revenue 94


TABLE 47 GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY SYSTEMS, THROUGH


2018 ($ MILLIONS) 94


FIGURE 24 GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY SYSTEMS,


2011-2018 ($ MILLIONS) 95


MARKET BY REGION 95


MARKET OVERVIEW 95


MARKET REVENUES 97


Oral Sustained Release Delivery 97


TABLE 48 GLOBAL REVENUE OF ORAL SUSTAINED RELEASE DRUG DELIVERY BY


REGION, THROUGH 2018 ($ MILLIONS) 97


FIGURE 25 GLOBAL REVENUE OF ORAL SUSTAINED RELEASE DRUG DELIVERY BY


REGION, 2011-2018 ($ MILLIONS) 97


Injectable Sustained Release Delivery 98


TABLE 49 GLOBAL REVENUE OF INJECTABLE SUSTAINED RELEASE DRUG DELIVERY


BY REGION, THROUGH 2018 ($ MILLIONS) 99


FIGURE 26 GLOBAL REVENUE OF INJECTABLE SUSTAINED RELEASE DRUG


DELIVERY BY REGION, 2011-2018 ($ MILLIONS) 99


Topical Sustained Release Delivery 99


TABLE 50 GLOBAL REVENUE OF TOPICAL SUSTAINED RELEASE DRUG DELIVERY BY


REGION, THROUGH 2018 ($ MILLIONS) 100


FIGURE 27 GLOBAL REVENUE OF TOPICAL SUSTAINED RELEASE DRUG DELIVERY


BY REGION, 2011-2018 ($ MILLIONS) 100


Prodrugs 100


TABLE 51 GLOBAL REVENUE OF PRODRUGS BY REGION, THROUGH 2018 ($


MILLIONS) 100


FIGURE 28 GLOBAL REVENUE OF PRODRUGS BY REGION, 2011-2018 ($ MILLIONS) 101


Implants and IUDs 101


TABLE 52 GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, THROUGH 2018


($ MILLIONS) 102


FIGURE 29 GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, 2011-2018 ($


MILLIONS) 102


Targeted Drug Delivery 103


TABLE 53 GLOBAL REVENUE OF LIPOSOMES DRUG DELIVERY BY REGION,


THROUGH 2018 ($ MILLIONS) 103


FIGURE 30 GLOBAL REVENUE OF LIPOSOMES DRUG DELIVERY BY REGION,


2011-2018 ($ MILLIONS) 103


TABLE 54 GLOBAL REVENUE OF NANOPARTICLES DRUG DELIVERY BY REGION,


THROUGH 2018 ($ MILLIONS) 104


FIGURE 31 GLOBAL REVENUE OF NANOPARTICLES DRUG DELIVERY BY REGION,


2011-2018 ($ MILLIONS) 104


TABLE 55 GLOBAL REVENUE OF MONOCLONAL ANTIBODIES DRUG DELIVERY BY


REGION, THROUGH 2018 ($ MILLIONS) 105


FIGURE 32 GLOBAL REVENUE OF MONOCLONAL ANTIBODIES DRUG DELIVERY BY


REGION, 2011-2018 ($ MILLIONS) 105


Polymeric Drug Delivery 106


Polymers 106


TABLE 56 GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION,


THROUGH 2018 ($ MILLIONS) 106


FIGURE 33 GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION,


2011-2018 ($ MILLIONS) 107


Pegylated Drugs 107


TABLE 57 GLOBAL REVENUE OF PEGYLATED DRUG DELIVERY BY REGION,


THROUGH 2018 ($ MILLIONS) 107


FIGURE 34 GLOBAL REVENUE OF PEGYLATED DRUG DELIVERY BY REGION,


2011-2018 ($ MILLIONS) 108


INDUSTRY STRUCTURE 108


SUSTAINED RELEASE 108


Market Leaders 108


TABLE 58 MAJOR MANUFACTURERS IN SUSTAINED RELEASE DRUG DELIVERY, 2012 108


Market Share 109


TABLE 59 MARKET SHARE OF THE MANUFACTURERS IN SUSTAINED DRUG


DELIVERY, 2012 (%) 109


FIGURE 35 MARKET SHARE OF THE MANUFACTURERS IN SUSTAINED DRUG


DELIVERY, 2012 (%) 109


PRODRUGS 110


Market Leaders 110


TABLE 60 MAJOR MANUFACTURERS OF PRODRUGS, 2012 110


Market Share 111


TABLE 61 MARKET SHARE OF THE MANUFACTURERS IN PRODRUGS, 2012 (%) 111


FIGURE 36 MARKET SHARE OF THE MANUFACTURERS IN PRODRUGS, 2012 (%) 111


IMPLANTS AND IUDS 112


Market Leaders 112


TABLE 62 MAJOR MANUFACTURERS OF IMPLANTS AND IUDS, 2012 112


Market Share 112


TABLE 63 MARKET SHARE OF THE MANUFACTURERS OF IMPLANTS AND IUDS, 2012


(%) 112


FIGURE 37 MARKET SHARE OF THE MANUFACTURERS OF IMPLANTS AND IUDS,


2012 (%) 112


TARGETED DELIVERY 113


Market Leaders 113


TABLE 64 MAJOR MANUFACTURERS IN TARGETED DRUG DELIVERY, 2012 113


Market Share 114


TABLE 65 MARKET SHARE OF THE MANUFACTURERS IN TARGETED DRUG


DELIVERY, 2012 (%) 114


FIGURE 38 MARKET SHARE OF THE MANUFACTURERS IN TARGETED DRUG


DELIVERY, 2012 (%) 114


POLYMERIC DRUG DELIVERY 115


Market Leaders 115


TABLE 66 MAJOR MANUFACTURERS IN POLYMERIC DRUG DELIVERY, 2012 115


Market Share 116


TABLE 67 MARKET SHARE OF THE MANUFACTURERS IN POLYMERIC DRUG


DELIVERY, 2012 (%) 116


FIGURE 39 MARKET SHARE OF THE MANUFACTURERS IN POLYMERIC DRUG


DELIVERY, 2012 (%) 116



CHAPTER 8 MARKET ANALYSIS FOR ADVANCED DRUG DELIVERY SYSTEMS BY ROUTE OF ADMINISTRATION 118

TABLE 68 GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS BY ROUTE


OF ADMINISTRATION, THROUGH 2018 ($ MILLIONS) 119


FIGURE 40 GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS BY ROUTE


OF ADMINISTRATION, 2011-2018 ($ MILLIONS) 119


MARKET BY TYPE 120


ORAL, TOPICAL AND INJECTABLE DRUG DELIVERIES 120


Market Overview 121


Market Revenue 122


TABLE 69 GLOBAL REVENUE OF ORAL, TOPICAL AND INJECTABLE DRUG DELIVERY


BY TYPE, THROUGH 2018 ($ MILLIONS) 122


FIGURE 41 GLOBAL REVENUE OF ORAL, TOPICAL AND INJECTABLE DRUG DELIVERY


BY TYPE, 2011-2018 ($ MILLIONS) 123


TRANSMUCOSAL DELIVERY SYSTEMS 123


Market Overview 124


Market Revenue 126


TABLE 70 GLOBAL REVENUE OF TRANSMUCOSAL DELIVERY SYSTEMS BY TYPE,


THROUGH 2018 ($ MILLIONS) 127


FIGURE 42 GLOBAL REVENUE OF TRANSMUCOSAL DELIVERY SYSTEMS BY TYPE,


2011-2018 ($ MILLIONS) 127


TRANSDERMAL DRUG DELIVERY SYSTEM 128


Market Overview 129


Market Revenue 129


TABLE 71 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY SYSTEMS,


THROUGH 2018 ($ MILLIONS) 129


FIGURE 43 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY SYSTEMS,


2011-2018 ($ MILLIONS) 129


MARKET BY REGION 130


MARKET OVERVIEW 130


MARKET REVENUE 131


Oral, Topical, Injectables 132


TABLE 72 GLOBAL REVENUE OF ORAL, TOPICAL AND INJECTABLE DRUG DELIVERY


BY REGION, THROUGH 2018 ($ MILLIONS) 132


FIGURE 44 GLOBAL REVENUE OF ORAL, TOPICAL AND INJECTABLE DRUG DELIVERY


BY REGION, 2011–2018 ($ MILLIONS) 132


Transmucosal Drug Delivery 133


TABLE 73 GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION,


THROUGH 2018 ($ MILLIONS) 133


FIGURE 45 GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION,


2011-2018 ($ MILLIONS) 133


Transdermal Drug Delivery 134


TABLE 74 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION,


THROUGH 2018 ($ MILLIONS) 134


FIGURE 46 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION,


2011-2018 ($ MILLIONS) 135


INDUSTRY STRUCTURE 135


ORAL, INJECTABLE AND TOPICAL DRUG DELIVERY 135


Market Leaders 135


TABLE 75 MAJOR MANUFACTURERS IN ORAL, INJECTABLE AND TOPICAL DRUG


DELIVERY, 2012 135


Market Share of Oral Drug Delivery 136


TABLE 76 MARKET SHARE FOR MANUFACTURERS OF ORAL DOSAGE FORMS, 2012


(%) 136


FIGURE 47 MARKET SHARE FOR MANUFACTURERS OF ORAL DOSAGE FORMS, 2012


(%) 137


Market Share of Injectable Drug Delivery 137


TABLE 77 MARKET SHARE FOR MANUFACTURERS OF INJECTABLE DOSAGE FORMS,


2012 (%) 137


FIGURE 48 MARKET SHARE FOR MANUFACTURERS OF INJECTABLE DOSAGE FORMS,


2012 (%) 138


Market Share of Topical Drug Delivery 138


TABLE 78 MARKET SHARE FOR MANUFACTURERS OF TOPICAL DOSAGE FORMS,


2012 (%) 138


FIGURE 49 MARKET SHARE FOR MANUFACTURERS OF TOPICAL DOSAGE FORMS,


2012 (%) 139


TRANSMUCOSAL DRUG DELIVERY 139


Market Leaders 139


TABLE 79 MAJOR MANUFACTURERS IN TRANSMUCOSAL DRUG DELIVERY 140


Market Share of Nasal Drug Delivery 141


TABLE 80 MARKET SHARE OF THE MANUFACTURERS IN PULMONARY AND NASAL


DRUG DELIVERY, 2012 (%) 141


FIGURE 50 MARKET SHARE OF THE MANUFACTURERS IN PULMONARY AND NASAL


DRUG DELIVERY, 2012 (%) 141


Market Share of Oral Mucosal/Buccal Drug Delivery 141


TABLE 81 MARKET SHARE OF THE MANUFACTURERS IN BUCCAL DRUG DELIVERY,


2012 (%) 142


FIGURE 51 MARKET SHARE OF THE MANUFACTURERS IN BUCCAL DRUG DELIVERY,


2012 (%) 142


Market Share of Rectal Drug Delivery 142


TABLE 82 MARKET SHARE OF THE MANUFACTURERS IN RECTAL DRUG DELIVERY,


2012 (%) 143


FIGURE 52 MARKET SHARE OF THE MANUFACTURERS IN RECTAL DRUG DELIVERY,


2012 (%) 143


Market Share of Ocular Drug Delivery 143


TABLE 83 MARKET SHARE OF THE MANUFACTURERS IN OCULAR DRUG DELIVERY,


2012 (%) 144


FIGURE 53 MARKET SHARE OF THE MANUFACTURERS IN OCULAR DRUG DELIVERY,


2012 (%) 144


Market Share of Vaginal Drug Delivery 144


TABLE 84 MARKET SHARE OF THE MANUFACTURERS IN VAGINAL DRUG DELIVERY,


2012 (%) 145


FIGURE 54 MARKET SHARE OF THE MANUFACTURERS IN VAGINAL DRUG DELIVERY,


2012 (%) 145


TRANSDERMAL DRUG DELIVERY 146


Market Leaders 146


TABLE 85 MAJOR MANUFACTURERS IN TRANSDERMAL DRUG DELIVERY, 2012 146


Market Share 146


TABLE 86 MARKET SHARE OF THE MANUFACTURERS IN TRANSDERMAL DRUG


DELIVERY, 2012 (%) 146


FIGURE 55 MARKET SHARE OF THE MANUFACTURERS IN TRANSDERMAL DRUG


DELIVERY, 2012 (%) 147



CHAPTER 9 MARKET BY END USERS 149

TABLE 87 GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY


APPLICATIONS, THROUGH 2018 ($ MILLIONS) 150


FIGURE 56 GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY


APPLICATIONS, 2011-2018 ($ MILLIONS) 150


CARDIOVASCULAR DISEASES 151


MARKET REVENUE 152


TABLE 88 GLOBAL MARKET FOR CARDIOVASCULAR DRUG DELIVERY SYSTEMS,


THROUGH 2018 ($ MILLIONS) 152


FIGURE 57 GLOBAL MARKET FOR CARDIOVASCULAR DRUG DELIVERY SYSTEMS,


2011-2018 ($ MILLIONS) 152


MARKET SHARE 153


TABLE 89 MARKET SHARE OF CARDIOVASCULAR DRUG DELIVERY SYSTEMS BY


REGION, 2012 (%) 153


FIGURE 58 MARKET SHARE OF CARDIOVASCULAR DRUG DELIVERY SYSTEMS BY


REGION, 2012 (%) 153


ONCOLOGY 154


MARKET REVENUE 155


TABLE 90 GLOBAL MARKET FOR ONCOLOGY DRUG DELIVERY SYSTEMS, THROUGH


2018 ($ MILLIONS) 155


FIGURE 59 GLOBAL MARKET FOR ONCOLOGY DRUG DELIVERY SYSTEMS,


2011-2018 ($ MILLIONS) 155


MARKET SHARE 156


TABLE 91 MARKET SHARE OF ONCOLOGY DRUG DELIVERY SYSTEMS BY REGION,


2012 (%) 156


FIGURE 60 MARKET SHARE OF ONCOLOGY DRUG DELIVERY SYSTEMS BY REGION,


2012 (%) 156


GASTROINTESTINAL SYSTEMS 156


MARKET REVENUE 157


TABLE 92 GLOBAL MARKET FOR GASTROINTESTINAL DRUG DELIVERY SYSTEMS,


THROUGH 2018 ($ MILLIONS) 157


FIGURE 61 GLOBAL MARKET FOR GASTROINTESTINAL DRUG DELIVERY SYSTEMS,


2011-2018 ($ MILLIONS) 157


MARKET SHARE 158


TABLE 93 GLOBAL SHARE OF REGIONS IN GASTROINTESTINAL DRUG DELIVERY


SYSTEMS, 2012 (%) 158


FIGURE 62 GLOBAL SHARE OF REGIONS IN GASTROINTESTINAL DRUG DELIVERY


SYSTEMS, 2012 (%) 158


UROLOGY 159


MARKET REVENUE 160


TABLE 94 GLOBAL MARKET FOR UROLOGY DRUG DELIVERY SYSTEMS, THROUGH


2018 ($ MILLIONS) 160


FIGURE 63 GLOBAL MARKET FOR UROLOGY DRUG DELIVERY SYSTEMS, 2011-2018


($ MILLIONS) 160


MARKET SHARE 160


TABLE 95 MARKET SHARE OF UROLOGY DRUG DELIVERY SYSTEMS BY REGION,


2012 (%) 161


FIGURE 64 MARKET SHARE OF UROLOGY DRUG DELIVERY SYSTEMS BY REGION,


2012 (%) 161


DIABETES 161


MARKET REVENUE 162


TABLE 96 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN DIABETES, THROUGH


2018 ($ MILLIONS) 162


FIGURE 65 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN DIABETES,


2011-2018 ($ MILLIONS) 162


MARKET SHARE 163


TABLE 97 MARKET SHARE OF DRUG DELIVERY SYSTEMS IN DIABETES BY REGION,


2012 (%) 163


FIGURE 66 MARKET SHARE OF DRUG DELIVERY SYSTEMS IN DIABETES BY REGION,


2012 (%) 163


CENTRAL NERVOUS SYSTEM 164


MARKET REVENUE 164


TABLE 98 GLOBAL MARKET FOR CENTRAL NERVOUS SYSTEM DRUG DELIVERY


SYSTEMS, THROUGH 2018 ($ MILLIONS) 165


FIGURE 67 GLOBAL MARKET FOR CENTRAL NERVOUS SYSTEM DRUG DELIVERY


SYSTEMS, 2011-2018 ($ MILLIONS) 165


MARKET SHARE 165


TABLE 99 MARKET SHARE OF CENTRAL NERVOUS SYSTEM DRUG DELIVERY


SYSTEMS BY REGION, 2012 (%) 166


FIGURE 68 MARKET SHARE OF CENTRAL NERVOUS SYSTEM DRUG DELIVERY


SYSTEMS BY REGION, 2012 (%) 166


RESPIRATORY DRUG DELIVERY SYSTEMS 166


MARKET REVENUE 167


TABLE 100 GLOBAL MARKET FOR RESPIRATORY DRUG DELIVERY SYSTEMS,


THROUGH 2018 ($ MILLIONS) 167


FIGURE 69 GLOBAL MARKET FOR RESPIRATORY DRUG DELIVERY SYSTEMS,


2011-2018 ($ MILLIONS) 167


MARKET SHARE 168


TABLE 101 MARKET SHARE IN RESPIRATORY DRUG DELIVERY SYSTEMS BY REGION,


2012 (%) 168


FIGURE 70 MARKET SHARE IN RESPIRATORY DRUG DELIVERY SYSTEMS BY REGION,


2012 (%) 168


INFLAMMATORY DISEASES AND ALLERGIES 168


MARKET REVENUE 169


TABLE 102 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR INFLAMMATORY


DISEASES AND ALLERGIES, THROUGH 2018 ($ MILLIONS) 169


FIGURE 71 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR INFLAMMATORY


DISEASES AND ALLERGIES, 2011-2018 ($ MILLIONS) 169


MARKET SHARE 170


TABLE 103 MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR INFLAMMATORY


DISEASES AND ALLERGIES BY REGION, 2012 (%) 170


FIGURE 72 MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR INFLAMMATORY


DISEASES AND ALLERGIES BY REGION, 2012 (%) 170


OPHTHALMOLOGY 171


MARKET REVENUE 172


TABLE 104 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY,


THROUGH 2018 ($ MILLIONS) 172


FIGURE 73 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY,


2011-2018 ($ MILLIONS) 172


MARKET SHARE 173


TABLE 105 MARKET SHARE OF DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY BY


REGION, 2012 (%) 173


FIGURE 74 MARKET SHARE OF DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY BY


REGION, 2012 (%) 173


VIRAL AND BACTERIAL DISEASES 174


MARKET REVENUE 174


TABLE 106 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR VIRAL AND


BACTERIAL DISEASES, THROUGH 2018 ($ MILLIONS) 174


FIGURE 75 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR VIRAL AND


BACTERIAL DISEASES, 2011-2018 ($ MILLIONS) 175


MARKET SHARE 175


TABLE 107 MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR VIRAL AND


BACTERIAL DISEASES BY REGION, 2012 (%) 175


FIGURE 76 MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR VIRAL AND


BACTERIAL DISEASES BY REGION, 2012 (%) 175


HORMONE REPLACEMENT THERAPY AND GYNECOLOGY 176


MARKET REVENUE 177


TABLE 108 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR HORMONE


REPLACEMENT THERAPY AND GYNECOLOGY, THROUGH 2018 ($ MILLIONS) 177


FIGURE 77 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR HORMONE


REPLACEMENT THERAPY AND GYNECOLOGY, 2011-2018 ($ MILLIONS) 177


MARKET SHARE 178


TABLE 109 MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR HORMONE


REPLACEMENT THERAPY AND GYNECOLOGY BY REGION, 2012 (%) 178


FIGURE 78 MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR HORMONE


REPLACEMENT THERAPY AND GYNECOLOGY BY REGION, 2012 (%) 178


OTHERS 179


MARKET REVENUE 180


TABLE 110 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN OTHER DISEASES,


THROUGH 2018 ($ MILLIONS) 180


FIGURE 79 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN OTHER DISEASES,


2911-2018 ($ MILLIONS) 180


MARKET SHARE 181


TABLE 111 MARKET SHARE OF DRUG DELIVERY SYSTEMS IN OTHER DISEASES,


2012 (%) 181


FIGURE 80 MARKET SHARE OF DRUG DELIVERY SYSTEMS IN OTHER DISEASES,


2012 (%) 181


MARKET SHARE OF APPLICATIONS 181


TABLE 112 MARKET SHARE OF DRUG DELIVERY SYSTEMS BY APPLICATIONS, 2012


(%) 181


FIGURE 81 MARKET SHARE OF DRUG DELIVERY SYSTEMS BY APPLICATIONS, 2012


(%) 182



CHAPTER 10 PATENT ANALYSIS 184

PATENTS BY YEAR 184


TABLE 113 NUMBER OF U.S. PATENTS BY YEAR, JANUARY 2009–JULY 2013 184


FIGURE 82 NUMBER OF U.S. PATENTS BY YEAR, JANUARY 2009-JULY 2013 184


PATENTS BY CATEGORY 185


TABLE 114 NUMBER OF U.S. PATENTS BY CATEGORY, JANUARY 2009-JULY 2013 185


FIGURE 83 NUMBER OF U.S. PATENTS BY CATEGORY, JANUARY 2009-JULY 2013 186


PATENTS BY TYPE 186


TABLE 115 NUMBER OF U.S. PATENTS BY TYPE, JANUARY 2009-JULY 2013 186


PATENTS BY COMPANY 187


TABLE 116 NUMBER OF U.S. PATENTS BY COMPANY, JANUARY 2009-JULY 2013 187


PATENTS BY COUNTRY 189


TABLE 117 NUMBER OF U.S. PATENTS BY COUNTRY, JANUARY 2009-JULY 2013 189


PATENTS BY ASSIGNEE 190


TABLE 118 NUMBER OF U.S. PATENTS BY ASSIGNEE, JANUARY 2009-JULY 2013 190


FIGURE 84 NUMBER OF U.S. PATENTS BY ASSIGNEE, JANUARY 2009-JULY 2013 190



CHAPTER 11 CURRENT SITUATION 192

CHAPTER 12 COMPANY PROFILES 196

3M COMPANY 196


ABBOTT LABORATORIES 196


ACTAVIS INC. 197


AKELA PHARMA INC. 197


AKORN, INC. 198


ALCON INC. 198


ALEXION PHARMACEUTICALS, INC. 199


ALKERMES 199


ALLERGAN INC. 199


AMGEN INC. 200


A.P. PHARMA 201


APTALIS PHARMA INC. 201


ASTELLAS PHARMA INC. 202


ASTRAZENECA PLC 202


ATON PHARMA 203


BAUSCH & LOMB 203


BAXTER INTERNATIONAL INC. 203


BAYER HEALTHCARE PHARMACEUTICALS 204


BIOGEN IDEC 204


BIOSANTE PHARMACEUTICALS, INC. 205


BOEHRINGER INGELHEIM 205


BOSTON SCIENTIFIC 206


BRISTOL MYERS SQUIBB 206


CELGENE CORPORATION 207


CEPHALON, INC. 207


COLUMBIA LABORATORIES, INC. 208


EISAI CO., LTD 208


ELAN DRUG TECHNOLOGIES 209


ENZON PHARMACEUTICALS 209


GENENTECH INC. 210


GENEREX BIOTECHNOLOGY CORPORATION 210


GENZYME CORPORATION 211


GILEAD SCIENCES, INC. 212


GLAXOSMITHKLINE PLC 212


HISAMITSU PHARMACEUTICAL CO., INC. 213


IMCLONE SYSTEMS INC. 213


JANSSEN BIOTECH, INC. 214


JOHNSON & JOHNSON 214


KEMPHARM, INC. 215


K.V. PHARMACEUTICAL CO. 215


LAVIPHARM CORPORATION 216


MANNKIND CORPORATION 216


MERCK & CO. 217


MYLAN LABORATORIES INC. 217


NEKTAR THERAPEUTICS 218


NEUROGESX INC. 218


NEWGEN BIOPHARMA 219


NOVARTIS AG 219


NOVAVAX, INC. 220


NOVEN PHARMACEUTICALS, INC. 220


NYCOMED US INC. 221


OSI PHARMACEUTICALS, INC. 221


PAR PHARMACEUTICAL COMPANIES, INC. 222


PDL BIOPHARMA, INC. 222


PFIZER INC. 223


QLT INC. 223


ROCHE HOLDING AG 224


SANOFI SA 224


TEVA PHARMACEUTICAL INDUSTRIES LTD. 225


THERAJECT, INC. 226


UMEWORLD LTD. 226


VALEANT PHARMACEUTICALS INTERNATIONAL, INC. 227


XEL PHARMACEUTICALS, INC. 227



CHAPTER 13 APPENDIX I 229



LIST OF TABLES

SUMMARY TABLE GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS,BY


REGION, THROUGH 2018 ($ MILLIONS) 7


TABLE 1 HISTORIC EVENTS IN DRUG DELIVERY 10


TABLE 2 ADVANTAGES AND DISADVANTAGES OF SUSTAINED RELEASE DRUG


DELIVERY 12


TABLE 3 CLASSIFICATION OF PRODRUGS 14


TABLE 4 ADVANTAGES AND DISADVANTAGES OF PRODRUGS 15


TABLE 5 ADVANTAGES AND DISADVANTAGES OF IMPLANTS AND IUDS 17


TABLE 6 ADVANTAGES AND DISADVANTAGES OF LIPOSOMES 19


TABLE 7 ADVANTAGES AND DISADVANTAGES OF MONOCLONAL ANTIBODIES 22


TABLE 8 ADVANTAGES AND DISADVANTAGES OF POLYMERS 23


TABLE 9 ADVANTAGES AND DISADVANTAGES OF PEGYLATION 24


TABLE 10 ADVANTAGES AND DISADVANTAGES OF ORAL DRUG DELIVERY 25


TABLE 11 ADVANTAGES AND DISADVANTAGES OF PARENTRAL DRUG DELIVERY 25


TABLE 12 ADVANTAGES AND DISADVANTAGES OF PULMONARY DRUG DELIVERY 26


TABLE 13 ADVANTAGES AND DISADVANTAGES OF NASAL DRUG DELIVERY 27


TABLE 14 ADVANTAGES AND DISADVANTAGES OF ORAL MUCOSAL DRUG DELIVERY 28


TABLE 15 ADVANTAGES AND DISADVANTAGES OF RECTAL DRUG DELIVERY 28


TABLE 16 ADVANTAGES AND DISADVANTAGES OF OCULAR DRUG DELIVERY 29


TABLE 17 ADVANTAGES AND DISADVANTAGES OF TRANSDERMAL DRUG DELIVERY 29


TABLE 18 FDA-APPROVED NEW PRODUCTS, 2009-JULY 2013 32


TABLE 19 PRODUCT RECALLS: DRUG DELIVERY, 2009-JUNE 2013 35


TABLE 20 SAFETY ALERTS, 2009 TO JUNE 2013 37


TABLE 21 NEW PARTNERSHIPS, MERGERS AND ACQUISITIONS, 2009-JUNE 2013 41


TABLE 22 NEW INNOVATIONS IN DRUG DELIVERY, 2009-JUNE 2013 43


TABLE 23 PIPELINE PRODUCTS FOR DRUG DELIVERY MARKET 44


TABLE 24 GLOBAL REVENUE OF DRUG DELIVERY SYSTEMS BY TYPE, THROUGH 2018


($ MILLIONS) 49


TABLE 25 MARKET SHARE OF DRUG DELIVERY SYSTEMS BY TYPE, 2012 (%) 50


TABLE 26 GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION,


THROUGH 2018 ($ MILLIONS) 53


TABLE 27 MARKET SHARE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION,


FOR 2012 (%) 54


TABLE 28 GLOBAL REVENUE OF PRODRUGS DRUG DELIVERY BY REGION, THROUGH


2018 ($ MILLIONS) 55


TABLE 29 MARKET SHARE OF PRODRUGS DRUG DELIVERY, BY REGION, 2012 (%) 56


TABLE 30 GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, THROUGH 2018 ($


MILLIONS) 58


TABLE 31 MARKET SHARE OF IMPLANTS AND IUDS BY REGION, 2012 (%) 59


TABLE 32 GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION,


THROUGH 2018 ($ MILLIONS) 62


TABLE 33 MARKET SHARE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2012 (%) 63


TABLE 34 GLOBAL REVENUE OF TARGETED DRUG DELIVERY BY REGION, THROUGH


2018 ($ MILLIONS) 65


TABLE 35 MARKET SHARE OF TARGETED DRUG DELIVERY BY REGION, 2012 (%) 66


TABLE 36 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION,


THROUGH 2018 ($ MILLIONS) 67


TABLE 37 MARKET SHARE OF TRANSDERMAL DRUG DELIVERY SYSTEM BY REGION,


2012 ($ MILLIONS) 68


TABLE 38 GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION, THROUGH


2018 ($ MILLIONS) 70


TABLE 39 MARKET SHARE OF POLYMERIC DRUG DELIVERY BY REGION, 2012 (%) 71


TABLE 40 GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS,


THROUGH 2018 ($ MILLIONS) 77


TABLE 41 MARKET SHARE OF DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS,


2012 (%) 79


TABLE 42 GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS BY


TECHNOLOGY, THROUGH 2018 ($ MILLIONS) 81


TABLE 43 GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY SYSTEMS BY


TYPE, THROUGH 2018 ($ MILLIONS) 85


TABLE 44 GLOBAL REVENUE OF PRODRUGS, THROUGH 2018 ($ MILLIONS) 86


TABLE 21 NEW PARTNERSHIPS, MERGERS AND ACQUISITIONS, 2009-JUNE 2013 87


TABLE 45 GLOBAL REVENUE OF IMPLANTS AND IUDS*, THROUGH 2018 ($ MILLIONS) 89


TABLE 46 GLOBAL REVENUE OF TARGETED DRUG DELIVERY SYSTEMS, THROUGH


2018 ($ MILLIONS) 92


TABLE 47 GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY SYSTEMS, THROUGH


2018 ($ MILLIONS) 94


TABLE 48 GLOBAL REVENUE OF ORAL SUSTAINED RELEASE DRUG DELIVERY BY


REGION, THROUGH 2018 ($ MILLIONS) 97


TABLE 49 GLOBAL REVENUE OF INJECTABLE SUSTAINED RELEASE DRUG DELIVERY


BY REGION, THROUGH 2018 ($ MILLIONS) 99


TABLE 50 GLOBAL REVENUE OF TOPICAL SUSTAINED RELEASE DRUG DELIVERY BY


REGION, THROUGH 2018 ($ MILLIONS) 100


TABLE 51 GLOBAL REVENUE OF PRODRUGS BY REGION, THROUGH 2018 ($


MILLIONS) 100


TABLE 52 GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, THROUGH 2018 ($


MILLIONS) 102


TABLE 53 GLOBAL REVENUE OF LIPOSOMES DRUG DELIVERY BY REGION, THROUGH


2018 ($ MILLIONS) 103


TABLE 54 GLOBAL REVENUE OF NANOPARTICLES DRUG DELIVERY BY REGION,


THROUGH 2018 ($ MILLIONS) 104


TABLE 55 GLOBAL REVENUE OF MONOCLONAL ANTIBODIES DRUG DELIVERY BY


REGION, THROUGH 2018 ($ MILLIONS) 105


TABLE 56 GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION, THROUGH


2018 ($ MILLIONS) 106


TABLE 57 GLOBAL REVENUE OF PEGYLATED DRUG DELIVERY BY REGION, THROUGH


2018 ($ MILLIONS) 107


TABLE 58 MAJOR MANUFACTURERS IN SUSTAINED RELEASE DRUG DELIVERY, 2012 108


TABLE 59 MARKET SHARE OF THE MANUFACTURERS IN SUSTAINED DRUG DELIVERY,


2012 (%) 109


TABLE 60 MAJOR MANUFACTURERS OF PRODRUGS, 2012 110


TABLE 61 MARKET SHARE OF THE MANUFACTURERS IN PRODRUGS, 2012 (%) 111


TABLE 62 MAJOR MANUFACTURERS OF IMPLANTS AND IUDS, 2012 112


TABLE 63 MARKET SHARE OF THE MANUFACTURERS OF IMPLANTS AND IUDS, 2012


(%) 112


TABLE 64 MAJOR MANUFACTURERS IN TARGETED DRUG DELIVERY, 2012 113


TABLE 65 MARKET SHARE OF THE MANUFACTURERS IN TARGETED DRUG DELIVERY,


2012 (%) 114


TABLE 66 MAJOR MANUFACTURERS IN POLYMERIC DRUG DELIVERY, 2012 115


TABLE 67 MARKET SHARE OF THE MANUFACTURERS IN POLYMERIC DRUG DELIVERY,


2012 (%) 116


TABLE 68 GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS BY ROUTE OF


ADMINISTRATION, THROUGH 2018 ($ MILLIONS) 119


TABLE 69 GLOBAL REVENUE OF ORAL, TOPICAL AND INJECTABLE DRUG DELIVERY


BY TYPE, THROUGH 2018 ($ MILLIONS) 122


TABLE 70 GLOBAL REVENUE OF TRANSMUCOSAL DELIVERY SYSTEMS BY TYPE,


THROUGH 2018 ($ MILLIONS) 127


TABLE 71 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY SYSTEMS,


THROUGH 2018 ($ MILLIONS) 129


TABLE 72 GLOBAL REVENUE OF ORAL, TOPICAL AND INJECTABLE DRUG DELIVERY


BY REGION, THROUGH 2018 ($ MILLIONS) 132


TABLE 73 GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION,


THROUGH 2018 ($ MILLIONS) 133


TABLE 74 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION,


THROUGH 2018 ($ MILLION




To order this report: Global Markets and Technologies for Advanced Drug Delivery Systems
http://www.reportlinker.com/p01940407/Global-Markets-and-Technologies-fo...



__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.